Pulmonary arterial hypertension: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PI3K 0
• NLRP3 0
• STAT3 0
• AKT 0
• HIF-1 0
• GLP-1 2
• mTOR 0
• CD19 2
• IL-6 0
• SGLT2 0
• CXCR4 0
• SIRT1 0
• ACE2 0
• AMPK 0
• HDAC 0
• HMGB1 0
• HSP90 0
• NRF2 0
• TNF 0
• YAP 0
• ABL1 0
• BCMA 2
• CTNNB1 0
• FAK 0
• RUNX1 0
• TLR4 0
• VEGF 0
• VHL 1
• ALK 1
• AR 0
• DPP-4 0
• ERK 0
• GIP 1
• GPX4 0
• HER3 0
• IGF1R 0
• JAK 0
• MAPK 0
• MDM2 0
• METTL3 0
• NOTCH3 0
• PARP 0
• PIK3CA 0
• PPAR 0
• PTEN 0
• STING 0
• TP53 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 847 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT04816604· Gossamer Bio USA, Inc.· Updated 5 Nov 2026

  “Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect study interpretation or the overall benefit-risk.”Registry text, quoted unchanged. Source

• Withdrawn

  A Feasibility Study of Supplemental Oxygen to Improve Pulmonary Hypertension in People With Intradialytic Hypoxemia

  NCT06327373· Duke University· Updated 3 Sept 2026

  “Funding not obtained”Registry text, quoted unchanged. Source

• Terminated

  Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH

  NCT05140525· Dr Sudarshan Rajagopal· Updated 3 Sept 2026

  “Sponsor Requested”Registry text, quoted unchanged. Source

• Terminated

  A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

  NCT01065454· Bayer· Updated 20 Aug 2026

  “The sponsor terminated the study for strategic reasons. This decision was not due to safety concerns for participants receiving treatment at the time the study was terminated.”Registry text, quoted unchanged. Source

• Withdrawn

  Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

  NCT07221513· Salubris Biotherapeutics Inc· Updated 15 May 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Suspended

  Exercise Training to Improve Cardiopulmonary Hemodynamics in Heart Failure Patients

  NCT04909008· Mayo Clinic· Updated 4 May 2026

  “Lack of recruitment”Registry text, quoted unchanged. Source

• Suspended

  Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  NCT07181382· GB002, Inc.· Updated 19 Mar 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Withdrawn

  Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH

  NCT05618093· University of California, Los Angeles· Updated 3 Feb 2026

  “Study device no longer available”Registry text, quoted unchanged. Source

• Withdrawn

  Pulmonary Vascular Hemodynamics Before and After Mitral Valve Procedures

  NCT04947384· University of Alabama at Birmingham· Updated 27 Jan 2026

  “PI moved to a different institution. Low enrollment rate.”Registry text, quoted unchanged. Source

• Terminated

  Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

  NCT05764265· Novartis Pharmaceuticals· Updated 27 Jan 2026

  “Sponsor Decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  2024-513613-12-00· Novartis Pharma AG· Source

• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-038)

  2025-521970-33-00· Merck Sharp & Dohme LLC· Source

• Effects of Inhaled Nitric Oxide on Sublingual Microcirculation in Patients With Right Ventricular Dysfunction After Cardiac Surgery

  NCT07918976· Southeast University, China· Source

• Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary Conditions

  NCT07915882· Michael Incze· Source

• A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)

  NCT07600723· Merck Sharp & Dohme LLC· Source

• Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  NCT04273945· Actelion· Source

• A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

  NCT04175600· Actelion· Source

• A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea

  NCT07890285· Janssen Korea, Ltd., Korea· Source

• A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

  NCT03492177· Actelion· Source

• A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

  NCT05179876· Actelion· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Mendelian Randomization Analysis 4
• CRISPR-Cas Systems 2
• Gene Expression Profiling 21
• Sequence Analysis, RNA 1
• Exome Sequencing 5
• Proteomics 10
• Metabolomics 11
• Immunohistochemistry 1
• Positron-Emission Tomography 2
• Magnetic Resonance Imaging 15
• Machine Learning 15
• Deep Learning 2
• Cohort Studies 18
• Genome-Wide Association Study 7

See which targets of this disease your abstract mentions, and go to the people working on them.